comprehensive -WSS

comprehensive

author：explore 2025-09-02 22:22:12 - browse：77861

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Crinetics acromegaly drug succeeds in late

hotspot

https://cbu01.alicdn.com/img/ibank/2016/539/257/3021752935_719793430.220x220xz.jpg

WSS

Merck CEO won’t testify in Senate, citing no expertise in drug prices

'Make People Better': The CRISPR babies story you probably don't know

'Make People Better': The CRISPR babies story you probably don't know

Snackable artificial intelligence, expert AI, and the pharma industry

Humana’s losses in Medicare Advantage tank its stock

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

https://cbu01.alicdn.com/img/ibank/2016/539/257/3021752935_719793430.220x220xz.jpg

Moonlake's readout produced a cash windfall. Risks remain

Investment in vaccine development is lagging, report finds

Affirmative action in medical school literally saved lives

AstraZeneca chief proposes a novel edit to the drug pricing bill

Activists slam private health insurers over coverage restrictions

What American doctors can learn from their Israeli counterparts

Virginia high school admissions case could be legal follow

Wegovy leads to weight loss. Can it treat depression, too?

Hepatitis C has a cure — but many Americans still lack access to it

10 reasons why health care startups fail

hotspot

Why Novartis is changing the name of its research labs

Health Care Service Corp to buy Cigna Medicare Advantage plans

Medicare drug price negotiation legal challenge met with skepticism

Biogen walks away from Aduhelm, years after polarizing approval

AstraZeneca chief proposes a novel edit to the drug pricing bill

A new House health package & hospitals’ new site

leisure time

hotspot

https://cbu01.alicdn.com/img/ibank/2016/539/257/3021752935_719793430.220x220xz.jpg

focus